PBE — Invesco Biotechnology & Genome ETF
Data updated: 2026-07-13
PBE — Invesco Biotechnology & Genome ETF data: holdings, portfolio allocation, expenses, performance, cashflows, risk and SEC filings. United States Health Care Equity · $247.38M AUM · 0.58% expense ratio · 29.1% 1-yr return. From SEC regulatory filings.
PBE Fund Overview
PBE — Invesco Biotechnology & Genome ETF is a US ETF managed by Invesco Exchange-Traded Fund Trust, categorised as United States Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US ETF
- Manager: Invesco Exchange-Traded Fund Trust
- Category: United States Health Care Equity
- Assets under management: $247.38M
- 1-year return: 29.1%
- Ticker: PBE
- SEC CIK: 0001209466
- SEC series ID: S000003026
- Share class ID: C000008293
PBE Holdings
Top 10 holdings of Invesco Biotechnology & Genome ETF by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Invesco Private Prime Fund | 10.92% |
| United Therapeutics Corp. | 6.28% |
| Illumina, Inc. | 5.37% |
| Biogen Inc. | 5.05% |
| Incyte Corp. | 4.91% |
| Alnylam Pharmaceuticals, Inc. | 4.84% |
| Regeneron Pharmaceuticals, Inc. | 4.77% |
| Amgen Inc. | 4.71% |
| Gilead Sciences, Inc. | 4.62% |
| Invesco Private Government Fund | 4.20% |
PBE Portfolio Allocation
Asset-class allocation of Invesco Biotechnology & Genome ETF by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 100.1% |
| Cash & Equivalents | 15.2% |
PBE Performance
Total returns for PBE (as of 2026-08-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | -3.0% |
| 1 year | 29.1% |
| 3 years (annualised) | 8.8% |
| 5 years (annualised) | 1.3% |
PBE Risk Information
Risk metrics for PBE, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 13.8%
PBE Costs and Fees
PBE costs about $58 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.58%
- Gross expense ratio: 0.58%
- Portfolio turnover: 94%
- Brokerage commissions: 6.25 bps of average net assets (SEC N-CEN)
PBE Cashflows
Over the 12 months to 2026-04, Invesco Biotechnology & Genome ETF had net outflows of $29.14M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-04 | $18.19K |
| 2026-03 | −$5.42M |
| 2026-02 | −$2.47M |
| 2026-01 | $4.16M |
| 2025-12 | $833.89K |
| 2025-11 | $1.67M |
PBE Debt Constituents
No individual debt constituents are reported in Invesco Biotechnology & Genome ETF's latest SEC N-PORT filing.
PBE Prospectus and SEC Filings
Official Invesco Biotechnology & Genome ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other United States Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.